

Lessons from a Medical Readiness Journey

Army Lt. Col. Travis E. Whiteside, PharmD, MBA, BCPS

Commander, Forensic Toxicology Drug Testing Laboratory (FTDTL)

Tripler Army Medical Center, Hawaii

6 November 2025 11:30 a.m. – 12:30 p.m. ET

UNCLASSIFIED



Presenter



Army Lt. Col. Travis E. Whiteside, PharmD, MBA, BCPS

Commander, Forensic Toxicology Drug Testing Laboratory (FTDTL)


Tripler Army Medical Center

U.S. Army

Hawaii



Lt. Col. Travis E. Whiteside, PharmD, MBA, BCPS



Lt. Col. Travis Whiteside currently serves as the Commander, Forensic Toxicology Drug Testing Lab (FTDTL), Tripler Army Medical Center (TAMC), HI.

Lt. Col. Whiteside is an Army Brat who enlisted in the Army in 1999 as a Combat Engineer. He separated in 2003 to attend Auburn University where he earned a Doctor of Pharmacy and Bachelor of Science in Laboratory Technology. He returned to Active Duty in 2011 after commissioning via a Health Professions Scholarship Program (HPSP) / Reserve Officers' Training Corps (ROTC) scholarship. He completed a post-graduate Pharmacy Practice Residency (PGY-1) at Brooke Army Medical Center (BAMC) in 2015 and is a Board-Certified Pharmacotherapy Specialist (BCPS). He went on to earn a Master of Business Administration from the College of William & Mary in Virginia in 2023.

Lt. Col. Whiteside's military assignments include: Deputy Chief, Department of Pharmacy, Tripler Army Medical Center (TAMC), HI; Brigade Pharmacist, 44th Medical Brigade, and Clinical Pharmacist at Womack Army Medical Center (WAMC), Fort Bragg, NC; Chief, Department of Pharmacy at McDonald Army Health Center (MCAHC) and Pharmacy Lead Advisor, Tidewater Multi-Service Market at Joint Base Langley-Eustis (JBLE), VA; Assistant Chief Pharmacy Branch, Medical Center of Excellence (MedCoE) and Pharmacology Instructor for the Interservice Physician Assistant Program (IPAP) at Joint Base San Antonio (JBSA), TX; 10th Mountain Division Pharmacist and the Afghan National Security Forces (ANSF) Senior Medical Development Advisor for Regional Command East (RC-E) in Afghanistan; Officer in Charge of Inpatient Pharmacy at Landstuhl Regional Medical Center (LRMC), Germany; Section Leader and Team Leader, 20th Engineer Battalion, 1st Cavalry Division, Ft. Hood, TX.



Disclosures



- Lt. Col. Travis Whiteside has no relevant financial or non-financial relationships to disclose relating to the content of this activity.
- The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of Defense, nor the U.S. Government.
- This continuing education activity is managed and accredited by the Defense Health Agency, J-7, Continuing Education Program Office (DHA, J-7, CEPO). DHA, J-7, CEPO and all accrediting organizations do not support or endorse any product or service mentioned in this activity.
- DHA, J-7, CEPO staff, as well as activity planners and reviewers have no relevant financial or non-financial relationships to disclose.
- Commercial support was not received for this activity.



Learning Objectives



At the conclusion of this activity, participants will be able to:

- 1. Discuss Geographic Combatant Commands (GCC), deployment medical eligibility criteria (MEC), and deployment limiting medical conditions (DLMC).
- 2. Summarize the Department of Defense's (DoD) medical readiness screening process.
- 3. Apply existing data tools to proactively address undetected DLMCs.
- 4. Review the undetected DLMC dilemma.
- 5. Recognize barriers to accurately quantifying medical readiness.



2011-2015: Germany to Afghanistan


















2015-2018: Joint Base San Antonio

"priority one is readiness"





 $https://www.army.mil/article/144934/u_s_army_medical_department_center_and_school_designated_an_army_center_of_excellence_coe$

https://www.army.mil/article/166838/csa_milley_readiness_is_my_no_1_priority https://www.bostonglobe.com/opinion/editorials/2015/01/05/mass-hospitals-show-how-fix-military-medical-care/2IWh1zeNGC2goyYXhoOKeP/story.html



2018-2021: Joint Base Langely Eustis









Army Polypharmacy & PolyMART







s M	10/15/1	1962 Maintenance Medication RX Warning (04/15/2022 MTF	BETA-ADRENERGIC BLOCKING AGENTS	523430059: METOPROLOL TARTRATE 25MG TABLET	ORAL 0	60.000
6 M				ANTICONVULSANTS		ORAL O	90.000
7 M		1962 Greater Than 45 Days Supply Warning (ORAL O	30.000
8 M						ORAL O	30.000
9 M						ORAL O	30.000
0 M						ORAL O	90.000
n M						DRAL 10	30.000
2 M						ORAL 0	60.000
3 M	_			ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S		ORAL 0	90.000
4 M							
				ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S		ORAL 0	90.000
5 M						ORAL 0	30.000
6 M						ORAL 0	90.000
7 M						ORAL 0	30.000
8 M				ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT		ORAL 0	90.000
9 M				ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT		ORAL 0	90.000
20 M						ORAL 0	90.000
21 M						ORAL 0	90.000
22 M				TOPICAL ANTINEOPLASTIC PREMALIGNANT LESION A		TOPICAL 0	30.000
23 M					807770273; COVID-19 VACC,MRNA(MODERNA)/PF 100MCG/0.5 VIAI		0.250
24 M			3/07/2022 MTF	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)		ORAL 0	90.000
25 M						ORAL 0	540.000
26 M				SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)		ORAL 0	90.000
27 M			6/03/2022 MTF	ANTICONVULSANTS	5234300312 GABAPENTIN 300MG CAPSULE	ORAL 0	540.000
28 M			4/06/2022 MTF	THYROID HORMONES	000744552 LEVOTHYROXINE SODIUM 50MCG TABLET	ORAL 0	90.000
29 F	12/20/	978 Medication Always Flagged 0	6/07/2022 MTF	LEUKOTRIENE RECEPTOR ANTAGONISTS	4229106219 MONTELUKAST SODIUM 10MG TABLET	ORAL 0	90.000
30 M	06/21/	978 Maintenance Medication RX Warning (5/01/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S)	5976201550 ATORVASTATIN CALCIUM 10MG TABLET	ORAL 0	90.000
31 M	06/21/	978 Maintenance Medication RX Warning (5/01/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S)	5976201550 ATORVASTATIN CALCIUM 10MG TABLET	ORAL 0	90.000
32 M	05/11/	983 Medication Always Flagged (3/17/2022 MTF	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NAR(4229105695 METHYLPHENIDATE HCL 27MG TAB ER 24	ORAL 2	30.000
33 M				TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NAR(ORAL 2	90.000
34 M			01/14/			NJECTION 0	2.000
35 M			3/08i 22 M	TA- RF (RG) SLOCK RAG TS		ORAL 0	30.000
36 M			3/10i 22 M	VI ANTS		ORAL 5	60.000
37 M			3715 22 N	PIOID VIA ESIO		ORAL 4	60.000
38 M			3/29i	ITICI VUL		ORAL %	90.000
M ea	_					ORAL O	30.000
M 04				ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT N		ORAL O	30.000
11 M				SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)		ORAL O	30.000
12 M	04/06/				7000937367 LOSARTAN/HYDROCHLOROTHIAZIDE 50-12.5MG TABL		90.000
13 M				BETA-AUMENERGIC BLOCKING AGENTS		ORAL O	30.000
14 M						ORAL 5	90.000
15 M						ORAL 4	60.000
16 M						ORAL 0	60.000
17 M						ORAL 0	360.000
18 M						NHALATIO'0	240.000
is M	06/07/			ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S		ORAL 0	90.000
0 M				ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S		ORAL 0	90.000
i M	_	-				ORAL 0	60.000
1 M							0.250
3 F					7807770273; COVID-19 VACC,MRNA(MODERNA)/PF 100MCG/0.5 VIAI I		90.000
				SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (S THIAZIDE AND RELATED DIURETICS		ORAL 0	90.000
4 M	111067						
8 M	11/06/	270 Manierance Medication FA Warning 0				ORAL 0	90.000
6 M						ORAL 4	30.000
7 M		The state of the s	THEOLEGE ISSUE	CHECKS THE STATE OF THE STATE O	TOOOGO TENEDEN NEEDED TENEDEN TOOLET	U1 11 10 V	90.000
M 8				ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT N		ORAL 0	90.000
M es				SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)		ORAL O	90.000
50 F				SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNF		ORAL 0	120.000
01 F					003781355C TRIAMTERENE/HYDROCHLOROTHIAZID 75MG-50MG		90,000 13
Sou	rce: Pl	harmacy Operations Division (POD) Analytics	Support	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT		ORAL 0	30.000
53 F	06/13/1	1368 Iviedication Always Hagged 0	412412022 MTF	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNE	6042301648 DULUXETINE MUL 20MG CAPSULE DR	ORAL 0	120.000



2021-2024: Fort Bragg





Medical Readiness (1 of 2)

- Medical Readiness, Defined
- Medical Readiness Programs:
 - DoDI 6025.19: Individual Medical Readiness (IMR) Program
 - o IMR Categories
 - o IMR Medical Monitoring Requirements
 - Military Services;
 - Air-Force: Aeromedical Services Information Management System (ASIMS)
 - Army: Medical Protection System (MEDPROS)
 - Navy, Marines, Coast Guard: Medical Readiness Reporting System (MRRS)
 - Delivery of Care: Defense Health Agency (DHA)
- Medical Eligibility Criteria (MEC):
 - DoDI 6490.07: Deployment-Limiting Medical Conditions for Service Members and DoD Civilian Employees
 - Military Services
 - Geographic Combatant Command (GCC)

15

Medical Readiness vs. Deployability

	Deployable	Deployable with Limitations	Temporary Non-Deployable	Permanent Non-Deployable
Fully Medically Ready (FMR)	 (a) Current DoD PHA (b) DRC 1 (c) DRC 2 (d) Immunization(s) current (e) Lab current (f) Equipment current (g) No DLMC 	A SM with a medical condition that requires additional medical screening or who requires a medical waiver prior to deployment	N/A	N/A
Partially Medically Ready (PMR)	(a) Overdue PHA(b) DRC 4(c) Overdue immunization(s)(d) Overdue lab studies(e) Overdue medical equipment	N/A	N/A	N/A
Not Medically Ready (NMR)	N/A	N/A	 (a) DRC 3 (b) SM returns to full duty <12 months (c) Medical Condition That Limits Full Duty: temporary profile >30 days or is in a limited duty or temporary limited duty status. (d) Pregnancy (including postpartum) 	 (a) Permanent Limited Duty: A SM with a medical condition that permanently prevents deployment. (b) SM currently enrolled in the DES process after receiving a "not fit for duty" determination. (c) Permanent Profile Non-Duty Related Action Needed

Disability Evaluation System (DES); Deployment Limiting Medical Conditions (DLMC); Dental Readiness Category (DRC); Periodic Health Assessment (PHA); Service Member (SM)

Source: DoDI 6025.19 UNCLASSIFIED 16



Table 2–1 Medical readiness classification chart

MRC Short definition		Medical definition	Commander deployment status personnel determination	
MRC 1	Medically ready/deployable	Meets all medical readiness requirements and DRC 1 or 2 —Temporary profile ≤ 7 days	Not required.	
MRC 2	Partially medically ready/deployable	Soldier is deficient in one or more of the following: —Temporary profile between 8 and 30 days inclusive —Hearing Readiness Class 4 (current within 13 months) —Vision Readiness Class 4 (current within 15 months) —DNA (drawn/on file with DOD Repository) —HIV (drawn/validated with DOD Repository) —Immunizations current or valid exception (routine adult immunization profile, to include HepA, HepB, TD or TDaP, MMR, polio, varicella, influenza-seasonal and, if required rabies) —Individual medical equipment if required; 1MI, 2 pair eye glasses, MCEP-I, MWT, and hearing aid with batteries	Not required, default to deployable. Commanders may make a deployability determination that a Soldier with a temporary profile between 14 and 30 days is not deployable.	
MRC 3	Not medically ready/commander determines deployment status for: —Temporary profile >30 days (DL 1) —DRC 3 (DL 2)	Soldier is deficient in one or more of the following: DL 1-Temporary profile > 30 days DL 2-DRC 3 DL 3-Pregnancy or post-partum DL 4-Permanent profile indicating a MAR2 needed DL 5-Permanent profile indicating a MEB action is needed DL 6-Permanent profile indicating a non-duty re- lated action is needed DL 7-Permanent profiles with a deployment/as- signment restriction code (F, V, X, or Y)	DL 1 and 2: Soldier is not medically ready/commander determines deployment status. DL 3, 4, 5, and 6: Soldier is not medically ready/non-deployable. Unit commander cannot make a deployability determination for routine readiness reporting. DL 7: Soldier is not medically ready/non-deployable. Unit commander cannot make a deployability determination for routine readiness reporting. Upon receipt of an assigned mission, deployment status will be in accordance with CCMD policies.	
MRC 4	Not medically ready/deploy- able and commander deter- mines deployment status (default non-deployable)	Status is unknown Soldier is deficient in one of the following: -PHA (current within 15 months) -DRC 4 (current within 15 months)	Soldier is not medically ready/deployable and commander determines deployment status.	

HepA = Hepatitis A

HepB = Hepatitis B

MMR = Measles, mumps, and rubella

MWT = medical warning tags

TD = tetanus-diphtheria adult

TDaP= Tetanus, diphtheria, and acellular pertussis

AR 40-502 Medical Readiness

Color	Summary				
	Deployable, No Issues				
	Commanders Discretion				
	Not Deployable				

Medical Readiness vs. Deployability

	Modical Rodalitoss vs. Dopicyasinty						
	Deployable	Deployable with Limitations	Temporary Non-Deployable	Permanent Non-Deployable			
Fully Medically Ready (FMR)	(a) Current DoD PHA (b) DRC 1 (c) DRC 2 (d) Immuniz MRC1 urrent (e) Lab current (f) Equipment current (g) No DLMC	A SM with a medical condition that requires additional medical screening or who requires a medical wa MRC1 to deployment	N/A	N/A			
Partially Medically Ready (PMR)	(a) Overdue PHA (b) DRC 4 (c) Ove MRC2 and 4s) (d) Overdue lab studies (e) Overdue medical equipment	N/A	N/A	N/A			
Not Medically Ready (NMR)	N/A	N/A	(a) DRC 3 (b) SM returns to full duty <12 months (c) Medical Condition That Limits Full Duty: temperation That Limits days or is in a limited duty or temporary limited duty status. (d) Pregnancy (including post- partum)	(a) Permanent Limited Duty: A SM with a medical condition that permanently prevents deployment. (b) SM curr MRC3 lled in the DES process after receiving a "not fit for duty" determination. (c) Permanent Profile Non-Duty Related Action Needed			

Disability Evaluation System (DES); Deployment Limiting Medical Conditions (DLMC); Dental Readiness Category (DRC); Periodic Health Assessment (PHA); Service Member (SM)



Table 2-1 Medical readiness classification chart


MRC	Short definition	Medical definition
MRC 1	Medically ready/deployable	Meets all medical readiness requir DRC 1 or 2 —Temporary profile ≤ 7 days
MRC 2	Partially medically ready/deployable	Soldier is deficient in one or more of a Temporary profile between 8 and sive —Hearing Readiness Class 4 (curre months) —Vision Readiness Class 4 (curre months) —DNA (drawn/on file with DOD Re—HIV (drawn/validated with DOD III —Immunizations current or valid extine adult immunization profile, to in HepB, TD or TDaP, MMR, polio, valenza-seasonal and, if required rabile—Individual medical equipment if roair eye glasses, MCEP—I, MWT, a with batteries
MRC 3	Not medically ready/com- mander determines deploy- ment status for: —Temporary profile >30 days (DL 1) —DRC 3 (DL 2)	Soldier is deficient in one or more of DL 1–Temporary profile > 30 days DL 2–DRC 3 DL 3–Pregnancy or post-partum DL 4–Permanent profile indicating needed DL 5–Permanent profile indicating needed DL 6–Permanent profile indicating lated action is needed DL 7–Permanent profiles with a designment restriction code (F, V, X,
MRC 4	Not medically ready/deploy- able and commander deter- mines deployment status (default non-deployable)	Status is unknown Soldier is deficient in one of the fol -PHA (current within 15 months) -DRC 4 (current within 15 months)

HepA = Hepatitis A HepB = Hepatitis B

MMR = Measles, mumps, and rubella

MWT = medical warning tags TD = tetanus-diphtheria adult

TDaP= Tetanus, diphtheria, and acellular pertussis



Source: AR 40-502/Medical Protection System (MEDPROS

Medical Readiness (2 of 2)

- Medical Readiness, Defined
- Medical Readiness Programs:
 - DoDI 6025.19: Individual Medical Readiness (IMR) Program
 - IMR Categories
 - IMR Medical Monitoring Requirements
 - Military Services;
 - o Air-Force: Aeromedical Services Information Management System (ASIMS)
 - Army: Medical Protection System (MEDPROS)
 - Navy, Marines, Coast Guard: Medical Readiness Reporting System (MRRS)
 - Delivery of Care: Defense Health Agency (DHA)
- Medical Eligibility Criteria (MEC):
 - DoDI 6490.07: Deployment-Limiting Medical Conditions for Service Members and DoD Civilian Employees
 - Military Services
 - Geographic Combatant Command (GCC)

Deployment Limiting Medical Conditions (DLMC)

Deployment Limiting Health Conditions (DLHC)

- Behavioral health conditions (depression, anxiety, insomnia, ADHD, etc.)
- Respiratory conditions (OSA, asthma, etc.)
- Migraines
- Endocrine disorders (hypothyroidism, diabetes, hypogonadism, etc.)
- Hypertension
- Hyperlipidemia

Deployment Limiting Medications (DLM)

- Stimulants
- Injectables
- Temperature Controlled
- Immunosuppressants/ Immunomodulators
- Androgens
- Hypnotics
- Pain (gabapentinoids, opioids, etc.)

Source: https://www.dvidshub.net/about/copyright








Applying Army Polypharmacy & PolyMART






Current Number of Service Members:				48857			
Number of Ser	vice Members On F	Polypharmacy Re	port	676	1.38%		
Number of W	TU Service Member	s on Polypharma	cy Report:	8	0.02%		
	Current Polypha	rmacy SM Data		Cur	rent Polypharma	cy WTU SM Dat	a
Cohort	Number of SMs	Total Pop. Pct	Polypharmacy Pop. Pct.	Number of WTU	Total Pop. Pct	Polypharmacy Pop. Pct.	WTU Pop. Pct
Cohort I:	1	0.00%	0.15%	0	0.00%	0.00%	0.00%
Cohort 2:	49	0.10%	7.25%	1	0.00%	0.15%	12.50%
Cohort 3:	0	0.00%	0.00%	0	0.00%	0.00%	0.00%
Cohort 4:	0	0.00%	0.00%	0	0.00%	0.00%	0.00%
Cohort 5:	584	1.20%	86.39%	5	0.01%	0.74%	62.50%
Cohort 6:	37	0.08%	5.47%	2	0.00%	0.30%	25.00%
Cohort 7:	5	0.01%	0.74%	0	0.00%	0.00%	0.00%

s M	10215219	962 Maintenance Medication RX Warning	04/15/2022 MTF	BETA-ADRENERGIC BLOCKING AGENTS	523430059: METOPROLOL T	ARTRATE 25MG TARLET	ORAL	70	60.000
		962 Medication Always Flagged		ANTICONVULSANTS	6909708131 GABAPENTIN 10		ORAL	70	90.000
		962 Greater Than 45 Days Supply Warning		SKELETAL MUSCLE RELAXANTS	55111017915 TIZANIDINE HCL		ORAL	70	30.000
					_			70	
		962 Greater Than 45 Days Supply Warning		SKELETAL MUSCLE RELAXANTS	55111017915 TIZANIDINE HCL		ORAL	0	30.000
		62 Greater Than 45 Days Supply Warning		SKELETAL MUSCLE RELAXANTS	55111017915 TIZANIDINE HCL		ORAL	0	30.000
0 M		62 Medication Always Flagged		ANTICONVULSANTS	6909708131 GABAPENTIN 10		ORAL	70	90.000
		62 Greater Than 45 Days Supply Warning		SKELETAL MUSCLE RELAXANTS	[55111017915] TIZANIDINE HCL		ORAL	0	30.000
2 M		962 Maintenance Medication RX Warning		BETA-ADRENERGIC BLOCKING AGENTS	523430059: METOPROLOL T		ORAL	0	60.000
3 M	10715 19	962 Maintenance Medication RX Warning	06/05/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	4229106655 PRAVASTATIN S	ODIUM 10MG TABLET	ORAL	0	90.000
4 M	10/15/19	862 Maintenance Medication RX Warning	06/05/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	4229106655 PRAVASTATIN S	ODIUM 10MG TABLET	ORAL	0	90.000
5 M	10/15/19	962 Greater Than 45 Days Supply Warning	06/20/2022 RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915 TIZANIDINE HCL	2MG TABLET	ORAL	0	30.000
6 M	10/15/19	962 Medication Always Flagged	06/20/2022 RETAIL	ANTICONVULSANTS	6909708131 GABAPENTIN 10	0MG CAPSULE	ORAL	0	90.000
7 M	10/15/19	962 Greater Than 45 Days Supply Warning	06/20/2022 RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915 TIZANIDINE HCL	2MG TABLET	ORAL	0	30.000
8 M		76 Maintenance Medication RX Warning	03/04/2022 MTF	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT	005970040: TELMISARTAN 4	0MG TABLET	ORAL	0	90.000
9 M	12/17/ 3	76 Maintenance Medication RX Warning	03/04/2022 MTF	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT	005970039: TELMISARTAN 2	OMG TABLET	ORAL	0	90.000
		968 Maintenance Medication RX Warning		ANTIHYPERTENSIVES, ACE INHIBITORS	6818009803 LISINOPRIL 10MG	TABLET	ORAL	0	90.000
		968 Maintenance Medication RX Warning		ANTIHYPERTENSIVES, ACE INHIBITORS	6818009803 LISINOPRIL 10MG		ORAL	0	90.000
22 M		991 Medication Always Flagged		TOPICAL ANTINEOPLASTIC PREMALIGNANT LESION /			TOPICAL	70	30.000
23 M		976 Medication Always Flagged		COVID-19 VACCINES		MRNA(MODERNA)/PF 100MCG/0.5 VIA		30	0.250
24 M		772 Medication Always Flagged		SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)			ORAL	70	90.000
25 M		772 Medication Always Flagged		ANTICONVULSANTS	5234300312 GABAPENTIN 30		ORAL	70	540.000
26 M		72 Medication Always Flagged	06/03/2022 MTF		633040632: FLUOXETINE HC		ORAL	70	90.000
27 M		772 Medication Always Flagged	06/03/2022 MTF	TICCHE SANTS	52000 GABAPENTIN 30	ING CAPSH F	ORAL	70	540.000
28 M		975 Maintenance Medication RX Warning				E SODIUM 50MCG TABLET	ORAL	70	90.000
			04/06/2022 MTF		MONTELUKAST:		ORAL	70	90.000
		78 Medication Always Flagged	06/07/2022 MTF					70	
		78 Maintenance Medication RX Varning		AL Y JO JAN DAL JUG SI IHI		CALCIUM 10MG TABLET	ORAL	70	90.000
81 M		78 Maintenance Medication RX Warning		ANTIH ERLIPIO (IC-HMGCOA) DUCTASE INHIB(S		CALCIUM 10MG TABLET	ORAL	70	90.000
32 M		83 Medication Always Flagged		TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NAR			ORAL	2	30.000
33 M		83 Medication Always Flagged		TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NAR/			ORAL	2	90.000
		78 Epi Pen RX Warning	01/14i	JAPI .AY APY AI	4950205001 EPINEPHRIF 0.:		INJECTION	10	2.000
		78 Maintenance Medication RX Warning	03/08/ 22 N	TA- RF (RG) LOCK LAG IS		UCCINATE 25MG TAB ER 24H	ORAL	0	30.000
		78 Medication Always Flagged	03/10/ 22 M	WI ANTS	_ ,	IMG CAPSULE	ORAL	5	60.000
		78 Greater Than 45 Days Supply Warning	03/15 22 N	NOID IA ESIC		. 50MG TABLET	ORAL	[4	60.000
		78 Medication Always Flagged	03/29/	ITIC VU.		IMG CAPSULE	ORAL	5	90.000
		978 Maintenance Medication RX Warning		BETA-ADRENERGIC BLOCKING AGENTS		UCCINATE 25MG TAB ER 24H	ORAL	0	30.000
		78 Medication Always Flagged		ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT N			ORAL	0	30.000
		78 Medication Always Flagged		SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)			ORAL	0	30.000
12 M 1		78 Maintenance Medication RX Warning		ANGIOTENSIN RECEPTOR ANTAG-THIAZIDE DIURETII			ORAL	0	90.000
		78 Maintenance Medication RX Warning	05/10/2022 MTF	BETA-AURENERGIC BLOCKING AGENTS		UCCINATE 25MG TAB ER 24H	ORAL	0	30.000
14 M 1	04/06/19	78 Medication Always Flagged	06/28/2022 MTF	ANTICONVULSANTS	00071101668 PREGABALIN 150		ORAL	5	90.000
15 M	04/06/19	78 Greater Than 45 Days Supply Warning	06/29/2022 MTF	OPIOID ANALGESICS	6516206271 TRAMADOL HCL	. 50MG TABLET	ORAL	4	60.000
16 M 81	06/07/19	79 Maintenance Medication RX Warning	03/09/2022 MTF	THYROID HORMONES	0007451821 LEVOTHYROXINE	SODIUM 75MCG TABLET	ORAL	0	60.000
M 73	06/07/19	79 Medication Always Flagged	03/20/2022 RETAIL	ANTICONVULSANTS	6516201025 GABAPENTIN 30	0MG CAPSULE	ORAL	0	360.000
18 M 81	06/07/ 3	79 Medication Always Flagged	04/15/2022 MTF	GLUCOCORTICOIDS, ORALLY INHALED	70018619880 BUDESONIDE 0.2	5MG/2ML AMPUL-NEB	INHALATIO	00	240.000
M ea		79 Maintenance Medication RX Warning	04/23/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	523430022: SIMVASTATIN 10	MG TABLET	ORAL	0	90.000
M o		79 Maintenance Medication RX Warning		ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S			ORAL	0	90.000
a M		79 Maintenance Medication RX Warning		THYROID HORMONES	0007451821 LEVOTHYROXINE		ORAL	0	60.000
		79 Medication Always Flagged		COVID-19 VACCINES	_	MRNA(MODERNA)/PF 100MCG/0.5 VIA		S'0	0.250
				SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (ORAL	70	90.000
		978 Maintenance Medication RX Warning		THIAZIDE AND RELATED DIURETICS	*572370002: HYDROCHLORO	THIAZIDE 12.5MG CAPSULE	ORAL	0	90.000
				THIAZIDE AND RELATED DIURETICS	*572370002: HYDROCHLORO		ORAL	0	90.000
6 M		978 Maximum 10 Dose Warning		SEDATIVE-HYPNOTICS,NON-BARBITURATE	7109301550 ZOLPIDEM TAR1		ORAL	4	30.000
7 M		79 Maintenance of Oral Medication RX Marriag		CALCIUM CHANNEL BLOCKING AGENTS	5292999397: AMI ODIPINE PE		ORAL	70	90.000
	-	978 Medication Always Flagged	OHIEGIEGEE IVIII	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT N	TOOOGOOGI LEINES DII II GE DE	OTELLIC STRUCTURE TO THE CONTRACT OF THE CONTR	ORAL	rn e	90.000
				SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)			ORAL	70	90.000
		168 Medication Always Flagged		SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNI			ORAL	70	120,000
				POTASSIUM SPARING DIURETICS IN COMBINATION				70	90.000 23
Coltroot	(D) (200	rm dow Operations Bivision (DOD) Analytics		ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT				70	
Source:	A MILES	rmacy Operations Division (POD) Analytics	Support Hir				ORAL	70	90.000
3 F	06/13/19	968 Medication Always Flagged	04/24/2022 MTF	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNI	6042301645 DULOXETINE HC	L ZUMG CAPSULE DR	ORAL	U	120.000









Soldier is deficient in one or more of the following:

DL 1-Temporary profile > 30 days

DL 2-DRC 3

DL 3-Pregnancy or post-partum

DL 4-Permanent profile indicating a MAR2 needed

DL 5-Permanent profile indicating a MEB action is needed

DL 6-Permanent profile indicating a non-duty related action is needed

DL 7-Permanent profiles with a deployment/assignment restriction code (F, V, X, or Y)



DLHC Report (1 of 2)

- 1. Filter DMIS: Isolate clinic DMIS
- 2. Filter PCMs: Isolate partner PCMs
- **3. Filter HIC3 Descriptions:** Isolate medication classes likely to be deployment limiting medications (DLM), for example:
 - ANDROGENIC AGENTS
 - ANTI-ANXIETY BENZODIAZEPINES
 - ANTICOAGULANTS, COUMARIN TYPE
 - INSULINS
- **4. Filter Drug/Strength/Form:** Remove likely false positives (i.e., metformin, naloxone, gabapentin, doxepin, doxylamine, topiramate, etc.)
- 5. Filter Days Supply: Remove less than 10 to eliminate likely false positives (i.e., short course opioid and benzodiazepines)
- 6. Medically Ready? Cross reference with Medical Readiness Platform (i.e. MEDPROS, MRRS, etc.) to eliminate medically non-deployable

03/04/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
03/22/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
04/15/2022	MTF	BETA-ADRENERGIC BLOCKING AGENTS	523430059	METOPROLOL TARTRATE 25MG TABLET
04/19/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
04/19/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
04/19/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
05/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
05/20/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
05/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET

- If medically deployable and possess a recent history of identified DLMs, schedule for a virtual 30 min FTR appointment.
- Treat appointment primarily as an educational opportunity to discuss and document the risk of being potentially medically non-deployable or require a waiver.

04/04/2022 MTP THYROLD HORMONES 000/744002 LEVOTHYROXINE SOLIOM 00M/CG TABLE

Canned Statements:


- "Patient notified that they are prescribed a medication(s) that may indicate that they are potentially non-deployable or require a waiver to deploy, depending on the deployment area of responsibility."
- "Patient advised to prioritize health and not discontinue medications without consulting a provider."

	06/29/2022 MTF	OPIDID ANALGESICS	6516206271 TRAMADUL HCL 50MG TABLET
	03/09/2022 MTF	THYROID HORMONES	70007451821 LEVOTHYROXINE SODIUM 75MCG TABLET
	03/20/2022 RETAIL	ANTICONVULSANTS	6516201025 GABAPENTIN 300MG CAPSULE
	04/15/2022 MTF	GLUCOCORTICOIDS, ORALLY INHALED	F0018619880 BUDESONIDE 0.25MG/2ML AMPUL-NEB
	04/23/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHII	B(S*523430022: SIMVASTATIN 10MG TABLET
	04/23/2022 MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHII	B(S*523430022: SIMVASTATIN 10MG TABLET
	04/24/2022 MTF	THYROID HORMONES	0007451821 LEVOTHYROXINE SODIUM 75MCG TABLET
	05/01/2022 RETAIL	COVID-19 VACCINES	807770273: COVID-19 VACC,MRNA(MODERNA)/PF 100MCG/0.5 \
	05/26/2022 MTF	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITOR	S (\$1310700790 TRAZODONE HCL 50MG TABLET
	04/29/2022 MTF	THIAZIDE AND RELATED DIURETICS	572370002: HYDROCHLOROTHIAZIDE 12.5MG CAPSULE
	04/29/2022 MTF	THIAZIDE AND RELATED DIURETICS	572370002: HYDROCHLOROTHIAZIDE 12.5MG CAPSULE
	04/29/2022 MTF	SEDATIVE-HYPNOTICS,NON-BARBITURATE	7109301550 ZOLPIDEM TARTRATE 5MG TABLET
ning	04/29/2022 MTF	CALCIUM CHANNEL BLOCKING AGENTS	293000397 AMLODIPINE BESYLATE 5MG TABLET
in the last	04/29/2022 MTF	ANTIPSYCHOTICS, ATYP. D2 PARTIAL AGONIST/5H	TN 604290447: ARIPIPRAZOLE 5MG TABLET



CarePoint











This page contains dynamic content -- Highest Possible Classification is CUI




























- My Favorite Filters
 - Diabetes 2BCT82ABN DM 44MB DM
 - Dyslipidemia 2BCT82ABN LDL > 190 44MB LDL>190
 - Hypertension 2BCT82ABN HTN 44MB HTN
 - Opioid Management 44MB Opioid
- Quicklook 44 MB BMI 30
- Public Favorite Filters
- Main Page PHI Access PCMH Huddle Schedules
- Admission Registries
























DLM: SGT (E-5) Alphabet (1 of 4)

- 32-year-old female
- **Jobs:** 68P Radiology Specialist
- Pre-deployment Review: DEC21 (EUCOM)
- PMH: anxiety, depression, ADHD, migraines, neuropathic pain, IBS-D, and acne
- Medications:
 - Venlafaxine 75mg 3 capsules daily
 - Hydroxyzine 25mg at bedtime
 - Pregabalin 150mg BID
 - Meloxicam 7.5mg daily
 - o Baclofen 10 MG TID PRN muscle spasms
 - Erenumab (Aimovig) 140mg SUBQ monthly (not in history)
 - Magnesium Oxide 400 mg BID
 - o Riboflavin (Vitamin B₂) 100 mg BID
 - Dicyclomine 20mg BID
 - Sucralfate 1 gram QAM and up to for times per day as needed
 - Famotidine 40mg daily
 - o Cholecalciferol (Vitamin D₃), 1,000 units daily
 - Levonorgestrel (Mirena) IUD (placed 2016)





DLM: SGT (E-5) Alphabet (2 of 4)

- Pre-deployment Review:
 - SRP "Deployable With Limitations": OCT21
 - o Internal Review (Poland) "Waiver Required": DEC21
- Deployed to Poland Without Waiver: MAR22
- Medication Issue, Erenumab (Aimovig): MAR22
- Evacuated to Landstuhl for Acute Cholecystitis: MAY22
- Re-deployed: JUN22
- DLMC Appointment: NOV22





EXPRESS SCRIPTS® PHARMACY IS READY TO DELIVER FOR YOUR PATIENTS

Deployed Prescription Program (DPP)



- Don't Know!!
 - Service Members
 - Providers
 - Commanders
- Controlled Medication Prescriptions:
 - 90-day Supply
 - Provider DEA Number
 - o CII:
 - Form Must Be Mailed
 - Handwritten Signature
 - CIII-CV: Faxed, Mailed, or Phoned
- Refrigerated Medications: No
- Psychotropics:
 - 180-day Supply
 - Only Renewals Honored
 - Must See Provider While Deployed
- No Waiver = No Medication



DLHC Report (2 of 2)

- 1. Filter DMIS: Isolate clinic DMIS
- 2. Filter PCMs: Isolate partner PCMs
- **3. Filter HIC3 Descriptions:** Isolate medication classes likely to be deployment limiting medications (DLM), for example:
 - ANDROGENIC AGENTS
 - ANTI-ANXIETY BENZODIAZEPINES
 - ANTICOAGULANTS, COUMARIN TYPE
 - INSULINS
- **4. Filter Drug/Strength/Form:** Remove likely false positives (i.e., metformin, naloxone, gabapentin, doxepin, doxylamine, topiramate, etc.)
- **5. Filter Days Supply:** Remove less than 10 to eliminate likely false positives (i.e., short course opioid and benzodiazepines)
- 6. Medically Ready? Cross reference with Medical Readiness Platform (i.e. MEDPROS, MRRS, etc.) to eliminate medically non-deployable

03/04/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
03/22/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
04/15/2022	MTF	BETA-ADRENERGIC BLOCKING AGENTS	523430059	METOPROLOL TARTRATE 25MG TABLET
04/19/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
04/19/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
04/19/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
05/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
05/20/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
05/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
06/05/2022	MTF	BETA-ADRENERGIC BLOCKING AGENTS	523430059	METOPROLOL TARTRATE 25MG TABLET
06/05/2022	MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	4229106659	PRAVASTATIN SODIUM 10MG TABLET
06/05/2022	MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	4229106659	PRAVASTATIN SODIUM 10MG TABLET
06/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
06/20/2022	RETAIL	ANTICONVULSANTS	6909708131	GABAPENTIN 100MG CAPSULE
06/20/2022	RETAIL	SKELETAL MUSCLE RELAXANTS	55111017915	TIZANIDINE HCL 2MG TABLET
03/04/2022	MTF	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT		
03/04/2022	MTF	ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANT	005970039	TELMISARTAN 20MG TABLET
03/14/2022	MTF	ANTIHYPERTENSIVES, ACE INHIBITORS	6818009803	LISINOPRIL 10MG TABLET
05/24/2022	MTF	ANTIHYPERTENSIVES, ACE INHIBITORS	6818009803	LISINOPRIL 10MG TABLET
04/08/2022	RETAIL	TOPICAL ANTINEOPLASTIC PREMALIGNANT LESION A	5167240630	FLUOROURACIL 5% SOLUTION

- If medically deployable and possess a recent history of identified DLMs, schedule for a virtual 30 min FTR appointment.
- Treat appointment primarily as an educational opportunity to discuss and document the risk of being potentially medically non-deployable or require a waiver.

	1/2022	MTF	BETA-ADRENERGIC BLOCKING AGENTS	6042901391	METOPROLOL SUCCINATE 25MG TABER 24H
	15/2022	MTF	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT N		
	J411512022	MTF	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	633040632	FLUOXETINE HCL 40MG CAPSULE
	05/10/2022	MTF	ANGIOTENSIN RECEPTOR ANTAG. THIAZIDE DIURETIC		
	05/10/2022	MTF	BETA-ADRENERGIC BLOCKING AGENTS	6042901391	METOPROLOL SUCCINATE 25MG TAB ER 24H
	06/28/2022	MTF	ANTICONVULSANTS	00071101668	PREGABALIN 150MG CAPSULE
	06/29/2022	MTF	OPIOID ANALGESICS	6516206271	TRAMADOL HCL 50MG TABLET
	03/09/2022	MTF	THYROID HORMONES	0007451821	LEVOTHYROXINE SODIUM 75MCG TABLET
	03/20/2022	RETAIL	ANTICONVULSANTS	6516201025	GABAPENTIN 300MG CAPSULE
	04/15/2022	MTF	GLUCOCORTICOIDS, ORALLY INHALED	0018619880	BUDESONIDE 0.25MG/2ML AMPUL-NEB
	04/23/2022	MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	523430022	SIMVASTATIN 10MG TABLET
	04/23/2022	MTF	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(S	523430022	SIMVASTATIN 10MG TABLET
	04/24/2022	MTF	THYROID HORMONES	0007451821	LEVOTHYROXINE SODIUM 75MCG TABLET
	05/01/2022	RETAIL	COVID-19 VACCINES	807770273	COVID-19 VACC,MRNA(MODERNA)/PF 100MCG/0.5
	05/26/2022	MTF	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (S	1310700790	TRAZODONE HCL 50MG TABLET
	04/29/2022	MTF	THIAZIDE AND RELATED DIURETICS	572370002	HYDROCHLOROTHIAZIDE 12.5MG CAPSULE
	04/29/2022	MTF	THIAZIDE AND RELATED DIURETICS	572370002	HYDROCHLOROTHIAZIDE 12.5MG CAPSULE
	04/29/2022	MTF	SEDATIVE-HYPNOTICS,NON-BARBITURATE	7109301550	ZOLPIDEM TARTRATE 5MG TABLET
ing	04/29/2022	MTF	CALCIUM CHANNEL BLOCKING AGENTS	293000397	AMLODIPINE BESYLATE 5MG TABLET
110	04/29/2022	MTF	ANTIPSYCHOTICS. ATYP. D2 PARTIAL AGONIST/5HT N	604290447	ARIPIPRAZOLE 5MG TABLET

36




DLM: SGT (E-5) Alphabet (3 of 4)

MEDPROS: MRC2

Amber

for Dental and Vision (as of 29NOV22)

UNCLASSIFIED





DLM: SGT (E-5) Alphabet (4 of 4)

- DLMC Appointment: NOV22
- Medications:
 - Venlafaxine 75mg 3 capsules daily
 - o Gabapentin ER (Gralis) 600mg
 - o Baclofen 10 MG TID PRN muscle spasms
 - Erenumab (Aimovig) 140mg SUBQ monthly
 - Magnesium Oxide 400 mg BID
 - Zolmitriptan 5mg PRN nausea
 - Dicyclomine 20mg BID
 - Doxycycline 100mg BID
 - Turmeric 500mg daily
 - o Famotidine 40mg daily
 - Vitamin D₂ 1.25mg (50,000 units) weekly
 - Levonorgestrel (Mirena) IUD (placed 2016)

Canned Statements:

- "Patient notified that they are prescribed a medication(s) that may indicate that they are potentially non-deployable or require a waiver to deploy, depending on the deployment area of responsibility."
- "Patient advised to prioritize health and not discontinue medications without consulting a provider."

Main Points:

- Example of Undetected DLMCs
- Apply Data Tools to Identify Unaddressed Medical Conditions
- DPP Constraints
- Medication Education Opportunity
- Offer Additional Services
- Establish PA (Readiness Provider) Relationships








Hyperlipidemia: MAJ (0-4) Mike (1 of 5)

- 44-year-old male
- Jobs: 70H Medical Plans & Operations
- **PMH:** back and knee pain, TBI, and spine fracture
- Medications: None
- Labs (as of FEB23)
 - o TC 293 mg/dL
 - o LDL 202 mg/dL
 - HDL 42 mg/dL
 - o TG 200 mg/dL








Hyperlipidemia: MAJ (0-4) Mike (2 of 5)

MEDPROS: MRC3 Red

for Hearing (as of 28FEB23)

UNCLASSIFIED





Hyperlipidemia: MAJ (0-4) Mike (3 of 5)

FH: "first male in my family to live past 40-years of age"

- Diet:
 - Breakfast: English muffin with peanut butter, black coffee, or eggs, bacon, hash-brown, and fruit
 - Lunch: Lean Cuisine frozen meal or sandwich from Quiznos
 - Dinner: chicken with potatoes, 1 vegetarian meal per week
 - Snacks: rarely, grapes or nuts
 - Dinning Out: twice a week
 - Types of Beverages: water (8 cups) and coffee (black)
 - Supplements: denied
- Tobacco: denies
- Alcohol: not interested in reducing alcohol
 - Whiskey (750mL) on the weekends
 - Glass of wine daily
 - Beer (dinning out)
- Physical Activity:
 - Physical training 4-5 days/week; 2 days are cardio
 - Trail bike or roller blades on Saturdays for 20-60min



UNCLASSIFIED



Hyperlipidemia: MAJ (0-4) Mike (4 of 5)

• Blood Pressure: 137/97 mmHg; 88 bpm

• **Labs** (as of 1MAR23)

o HbA1c: 5.2%

o TC 259 mg/dL

o LDL 175 mg/dL

o HDL 36 mg/dL

o TG 216 mg/dL

ASCVD Risk Score: 5.2% (borderline)

Counselling/Education:

Physical Activity/Diet/Weight Loss

Alcohol Reduction/Cessation

Medications:

+ Rosuvastatin 10 mg daily

○ +Fish Oil 1000 mg BID





Hyperlipidemia: MAJ (0-4) Mike (5 of 5)

- Blood Pressure: 118/80 mmHg; 76 bpm ▼
- Diet: reduced sodium in his diet A
- Alcohol: quit beer ▲
- Physical Activity: joined a fitness group
- Counselling/Education:
 - Physical Activity/Diet/Weight Loss
 - Alcohol Reduction/Cessation
- Medications: Continued
 - Rosuvastatin 10 mg daily
 - Fish Oil 1000 mg BID
 - o Lisinopril 10 mg daily
- PCS'ed APR23

UNCLASSIFIED



Main Points:

- Example of Undetected DLMCs
- Apply Data Tools to Identify Unaddressed Medical Conditions
- Early Lifestyle Interventions
- Offer Additional Services
- Establish PA (Readiness Provider) Relationships



Goal: 90%

23%

Observed: 80%



The Department of Defense is overestimating its ability to project force due to undetected Deployment Limiting Medical Conditions





Key Takeaways



- Awareness of deployment medical echelons of care and an appreciation for the potential austerity of this medical care.
- Peripheral understand of medical readiness, how it is determined, and why it matters.
- Learned from my iterative attempts to address medical readiness.
- Appreciate the undetected DLMC dilemma.
- Recognize barriers to quantifying medical readiness.

UNCLASSIFIED 47



References (1 of 5)



Department of Defense. (2022). DoD instruction (DoDI) 6025.19, Individual Medical Readiness Program. Accessed May 20, 2024.

https://www.esd.whs.mil/portals/54/documents/dd/issuances/dodi/602519p.pdf

Defense Health Agency. Carepoint. Accessed May 15, 2024. https://carepoint.health.mil/SitePages/LandingPage.aspx

Express Scripts. (2023). Deployed Prescription Program Provider Brochure. Accessed May 15, 2024.

https://militaryrx.express-scripts.com/sites/default/files/2023-12/DPP Provider Brochure.pdf

Garamone, J. (2023). Vice chiefs talk recruiting shortfalls, readiness issues. US Department of Defense. Accessed May 20, 2024.

https://www.defense.gov/News/News-Stories/Article/Article/3369472/vice-chiefs-talk-recruitingshortfalls-readiness-issues/

Hale, T. (2016). CSA Milley: 'Readiness is my No. 1 priority'. U.S. Army. Accessed September 7, 2025.

https://www.army.mil/article/166838/csa_milley_readiness_is_my_no_1_priority



References (2 of 5)



Jackson, J. (2023). Will U.S. military recruitment struggles cripple response to wars? Newsweek. Accessed May 20, 2024.

https://www.newsweek.com/will-usmilitary-recruitment-struggles-cripple-response-wars-1789001

Medical Protection System (MEDPROS) .(2015). Army Medical Department (AMEDD). Accessed May 15, 2024.

https://medpros.mods.army.mil/medprosnew/

Military Health System. (2023). Deployment Limiting Health Conditions (DLHC) Report. Pharmacy Operations Division (POD) Analytics Support. https://health.mil/Military-Health-Topics/Access-Cost-Quality

OTSG/MEDCOM Policy Memo 15-039. (2015). Guidance for Managing Polypharmacy and Preventing Medication Overdose in Patients

Prescribed Psychotropic Medications and Central Nervous System Depressants. Department of the Army, Headquarters, United States

Army Medical Command. JBSA Fort Sam Houston, TX.



References (3 of 5)



POD Analytics Support (2025). Accessed September 7, 2025.

https://health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/POD-Analytics-Support

Rumbaugh, R. Defining readiness: background and issues for Congress. Congressional Research Service. (2017). Accessed May 20, 2024.

https://sgp.fas.org/crs/natsec/R44867.pdf

Statement by Lieutenant General Patricia D. Horoho. (2014). The Surgeon General United States Army Before the Senate Committee on Appropriations Subcommittee on Defense, Second Session, 113th Congress on Defense Health Program. Accessed September 7, 2025.

https://www.appropriations.senate.gov/imo/media/doc/hearings/Horoho's%20Testimony.pdf

U.S. Army Fort Bragg. (2023). 44th Medical Brigade. Accessed May 20, 2024. https://home.army.mil/bragg/units-tenants/xviii-airborne-co/44th-medical-brigade

US Army.(2023). Non-deployables as of 30 May 2023. U.S. Army G1. Accessed May 15, 2024.

US Department of Defense. (2010). DoD instruction (DoDI) 6490.07, deployment-limiting medical conditions for service members and DoD civilian employees.

Accessed May 20, 2024. https://www.esd.whs.mil/Portals/54/Documents/DD/issuances/dodi/649007p.pdf



References (4 of 5)



United States Africa Command (USAFRICOM). (2023). Africa Command instruction (ACI) 4200.09A, force health protection requirements and medical guidance for entry into the U.S. Africa Command theater. Accessed May 20, 2024. https://www.africom.mil/document/35296/aci420009b- forcehealthprotectionrequirementsandmedicalguidanceforentryintotheusafricomthea

United States Central Command (USCENTCOM). (2023). MOD17-TAB A: amplification of the minimal standards of fitness for deployment to the CENTCOM AOR.

Accessed May 20, 2024. https://www.centcom.mil/Portals/6/MEDICAL/MOD17_Tab_A.pdf

United States European Command (USEUCOM). (2019). Europe Command instruction (ECI) 4202.01, United States European Command (USEUCOM) theater medical entry requirements. Accessed May 20, 2024. https://govtribe.com/file/government-file/pws-attachment-26-eci-4202-dot-01-health-service-support-us-european-cc-theater-medicalentry-dot-pdf

United States Indo-Pacific Command. (2021). United States Indo-Pacific Command (USINDOPACOM) fiscal year (FY) 2021 force health protection guidance. Accessed May 20, 2024.

https://www.pacom.mil/Portals/55/Documents/pdf/J07_USINDOPACOM%20FY2021%20Force%20Health%20Protection%20Guidance%2023%20Oct%202020.pdf



References (5 of 5)



United States North Command (USNORTHCOM). (2014). NORAD and USNORTHCOM command instruction (NNCI) 44-163, individual medical readiness.

United States South Command. (2019). Amplification of the Minimal Standards of Fitness for Deployment to the United States South Command (USSOUTHCOM) area of responsibility (AOR). Accessed May 20, 2024.

https://www.southcom.mil/Portals/7/Documents/Operational%20Contract%20Support/USSOUTHCOM%20-%20ATTACHMENT%20B-

%20AMPLIFICATION%200F%20THE%20MINIMAL%20STANDARDS%20(002.pdf?ver=2019-06-14-142342-690)





Questions?



How to Obtain CE/CME Credit



2025 NOV Clinical Communities Speaker Series: Optimizing Patient-Centered Military-Specific Care

Credits are awarded by session. To claim CE/CME credit for the session(s) you attended, complete each evaluation survey and posttest before the evaluation period ends on **20 November 2025 at 11:59 PM Eastern Time**.

- 1. Visit the registration page at https://www.dhaj7-cepo.com/content/2025-nov-ccss. From there, register for the event or log in to your account if already registered.
- 2. Once logged in and registered, on the event page, select "Get Started" (located in the menu below the event title on desktop and at the bottom of the page on mobile devices). Note: This tab will not appear unless you are registered and logged in to your account.
- Under the "Get Started" tab, scroll down to a session you attended and select "Claim credit."
- 4. Proceed to take the evaluation and posttest to obtain your certificate after the session has ended.

Once you have been awarded credit, you can download your certificate anytime through <u>your account</u>. Any activity you register for but have yet to complete will be available under your <u>pending activities</u> until the evaluation period ends.

Questions? Email the DHA J-7 Continuing Education Program Office at dha.ncr.j7.mbx.cepo-cms-support@health.mil.